Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247723731> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2247723731 abstract "418 Background: Pancreatic neuroendocrine tumors (PNET) constitute about 3% of pancreatic neoplasms. In borderline resectable disease, there is a lack of data to support an optimal neoadjuvant approach for curative outcomes. We describe our institutional experience with a multimodality approach. Methods: We identified all patients with borderline resectable PNET, using NCCN criteria for adenocarcinoma of the pancreas, who received neoadjuvant therapy at our institution between 2000 and 2013. The reason for borderline status was noted. Neoadjuvant regimen, radiographic response, pathologic response, surgical margins, nodal harvest, number of positive nodes, and recurrence were all documented. Results: A total of 112 patients had undergone pancreatic resections for neuroendocrine tumors during the study period. Six patients had borderline resectable disease. The mean age was 55 years (24-70). They all received at least 1 cycle of Temodar and Xeloda. Three of the six patients also received concurrent 5-FU and radiation. There was radiographic evidence of treatment response in all patients. Five of six patients (83 %) had negative margin (R0) resection. Low volume miliary metastatic disease in the liver was detected in 1 patient at the time of surgery. The median number of lymph nodes harvested was 12. Half of the patients had node positive disease. On pathologic review, 4 patients had histologic evidence of a moderate response. All patients are alive and 5/6 are free of disease. Range of follow up is 3.0-4.32 years. The patient with metastatic disease has had no progression and is the only one who is currently receiving any form of treatment. Conclusions: Neoadjuvant Temodar and Xeloda ± radiation with 5-FU sensitization can lead to R0 resection with durable response in patients with borderline resectable PNET. To our knowledge, this is the first report of the use of multimodality therapy (neoadjuvant chemotherapy ± chemoradiation and surgery) in the treatment of borderline resectable PNET." @default.
- W2247723731 created "2016-06-24" @default.
- W2247723731 creator A5006838528 @default.
- W2247723731 creator A5007883302 @default.
- W2247723731 creator A5016061217 @default.
- W2247723731 creator A5035589941 @default.
- W2247723731 creator A5062142011 @default.
- W2247723731 creator A5068503288 @default.
- W2247723731 creator A5076398535 @default.
- W2247723731 creator A5089225736 @default.
- W2247723731 creator A5089391909 @default.
- W2247723731 date "2015-01-20" @default.
- W2247723731 modified "2023-09-27" @default.
- W2247723731 title "Multimodality management of borderline resectable pancreatic neuroendocrine tumors: Sentinel report of a single-institutional experience." @default.
- W2247723731 doi "https://doi.org/10.1200/jco.2015.33.3_suppl.418" @default.
- W2247723731 hasPublicationYear "2015" @default.
- W2247723731 type Work @default.
- W2247723731 sameAs 2247723731 @default.
- W2247723731 citedByCount "1" @default.
- W2247723731 countsByYear W22477237312021 @default.
- W2247723731 crossrefType "journal-article" @default.
- W2247723731 hasAuthorship W2247723731A5006838528 @default.
- W2247723731 hasAuthorship W2247723731A5007883302 @default.
- W2247723731 hasAuthorship W2247723731A5016061217 @default.
- W2247723731 hasAuthorship W2247723731A5035589941 @default.
- W2247723731 hasAuthorship W2247723731A5062142011 @default.
- W2247723731 hasAuthorship W2247723731A5068503288 @default.
- W2247723731 hasAuthorship W2247723731A5076398535 @default.
- W2247723731 hasAuthorship W2247723731A5089225736 @default.
- W2247723731 hasAuthorship W2247723731A5089391909 @default.
- W2247723731 hasConcept C121608353 @default.
- W2247723731 hasConcept C126322002 @default.
- W2247723731 hasConcept C126838900 @default.
- W2247723731 hasConcept C143998085 @default.
- W2247723731 hasConcept C2778292576 @default.
- W2247723731 hasConcept C2778764654 @default.
- W2247723731 hasConcept C2779066768 @default.
- W2247723731 hasConcept C2781182431 @default.
- W2247723731 hasConcept C2781413609 @default.
- W2247723731 hasConcept C530470458 @default.
- W2247723731 hasConcept C71924100 @default.
- W2247723731 hasConceptScore W2247723731C121608353 @default.
- W2247723731 hasConceptScore W2247723731C126322002 @default.
- W2247723731 hasConceptScore W2247723731C126838900 @default.
- W2247723731 hasConceptScore W2247723731C143998085 @default.
- W2247723731 hasConceptScore W2247723731C2778292576 @default.
- W2247723731 hasConceptScore W2247723731C2778764654 @default.
- W2247723731 hasConceptScore W2247723731C2779066768 @default.
- W2247723731 hasConceptScore W2247723731C2781182431 @default.
- W2247723731 hasConceptScore W2247723731C2781413609 @default.
- W2247723731 hasConceptScore W2247723731C530470458 @default.
- W2247723731 hasConceptScore W2247723731C71924100 @default.
- W2247723731 hasLocation W22477237311 @default.
- W2247723731 hasOpenAccess W2247723731 @default.
- W2247723731 hasPrimaryLocation W22477237311 @default.
- W2247723731 isParatext "false" @default.
- W2247723731 isRetracted "false" @default.
- W2247723731 magId "2247723731" @default.
- W2247723731 workType "article" @default.